Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3127804 in Participants With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are hospitalized with pneumonia, and presumed or confirmed COVID-19~* Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed)~Exclusion Criteria:~* Female participants must not be pregnant and/or lactating~* Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent mandatory ventilation (IMV), or are ineligible for IMV~* Have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study~* Are moribund irrespective of the provision of treatments~* Have a known history or show evidence of human immunodeficiency virus (HIV) and/or hepatitis~* Have recently undergone major surgery or central venous access device placement~* Have a significant bleeding disorder or active vasculitis~* Have experienced a thromboembolic event~* Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia~* Have a serious, nonhealing wound, peptic ulcer, or bone fracture~* Have liver cirrhosis~* Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins~* Have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3127804 (Type: EXPERIMENTAL): Participants received 20 milligrams (mg) per kilogram (kg) of LY3127804 as an intravenous (IV) infusion on Days 1 and 15.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received 20 mg/kg of Placebo as an IV infusion on Days 1 and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).